Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease.

NPJ Genom Med · 2022 · PMC8993824 · PMID 35396391

Europe PMC DOI

hedged sentence

0.2250

closest p · 4.5× alpha

0.2250

boldest claim

The sentences

did not reach statistical significancep = 0.225not close (p > 0.1)

In CGMS participants with at least one G551D variant ( n = 79), rs7512462 did not reach statistical significance at the 0.05 level with Saknorm (effect size = 0.185, p = 0.225, Supplementary Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.